TOP trial. A randomised phase iii clinical trial of trastuzumab (Herceptin) optimization in patients with locally advanced and/or metastatic breast cancer overexpressing HER2 [human epidermal growth factor receptor 2] after a first line chemotherapy plus trastuzumab.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TOP
- 31 Aug 2018 Biomarkers information updated
- 10 Jun 2015 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently.
- 07 Apr 2008 New trial record.